---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-065378"
form_type: "8-K"
ticker: "TARA"
cik: "0001359931"
company_name: "Protara Therapeutics, Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:12:02.458620+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Protara Therapeutics Q2 net loss $9.5M; cash $89.6M; pipeline milestones on track

## Summary
- Net loss $9.5M ($0.45/share) vs $11.3M ($1.00/share) in Q2 2023; R&D expenses decreased to $6.4M.
- Cash and investments $89.6M at June 30, including $42M net from April private placement; funding expected into 2026.
- Expects preliminary data from 6-month evaluable patients in ADVANCED-2 trial (TARA-002 in NMIBC) in Q4 2024.
- Pivotal trial dosing for IV Choline Chloride in PN patients expected to begin Q1 2025 after FDA alignment.
- Appointed Lisa Schlesinger as VP, Head of New Product Development and Market Access in June 2024.

## SEC filing metadata
- accession: 0001213900-24-065378
- form_type: 8-K
- ticker: TARA
- cik: 0001359931
- company_name: Protara Therapeutics, Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1359931/000121390024065378/0001213900-24-065378-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1359931/000121390024065378/ea0210016-8k_protara.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-065378
- JSON: https://secwatch.observer/filing/0001213900-24-065378.json
- Plain text: https://secwatch.observer/filing/0001213900-24-065378.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.